RightFit
RecruitingNot applicable

Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia

Using Real Time Mobile Health Approaches to Understand and Promote Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
14 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

  • Time periods mentioned: 28 days
  • Procedures mentioned: Questionnaires, Interviews

Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.

Show the study's own words
  • "Participants in the study will electronically-monitor 6-MP adherence with eCAPs for 28 days (approximately one month to establish baseline adherence before introducing the intervention)."
  • "AYAs and caregivers will complete a brief acceptability survey electronically via REDCAP, rating ADAPTS on a 5-point Likert scale to assess satisfaction, perceived appropriateness, perceive positive effects, perceived demands, and potential for future use."
  • "Exit interviews will also be conducted, audio-recorded, and transcribed to further assess acceptability."
Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This small study tests a mobile tool that gives support at the right time to help teens and young adults take their chemotherapy pills. It is for people ages 14–29 with acute lymphoblastic leukemia (ALL) or lymphoma, two types of cancer. The study looks at whether the tool is practical to use and whether users find it acceptable.

This is a small-scale micro-randomized clinical trial of a new mobile just-in-time adaptive intervention (JITAI) designed to promote oral chemotherapy adherence in adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL). The goals of this study are to determine intervention feasibility and acceptability.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Patients must be ages 14–29.
  • Patients must have ALL or lymphoma.
  • Patients must be in maintenance treatment, which helps keep cancer from coming back. They must have finished at least one treatment cycle and have at least one month left.
  • Patients must be prescribed 6-mercaptopurine (6MP), a chemotherapy medicine.
  • Patients must be able to use English.
  • Patients under 18 must have a caregiver’s informed consent, meaning permission after learning about the study.
  • Caregivers must be chosen by the patient as a main caregiver involved in their cancer care. This can be a parent, relative, partner, or friend.
  • Caregivers must be able to use English.

Who can't join

  • Patients cannot join if the medical team finds that thinking or understanding problems would limit their ability to complete study tasks.
  • Patients and caregivers cannot join if they do not meet the requirements for their group.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

AYA Inclusion Criteria: * Ages 14-29 * Diagnosed with acute lymphoblastic leukemia (ALL) or lymphoma * In the maintenance phase, completed at least one cycle and has at least one month of maintenance therapy remaining. * Prescribed 6-mercaptopurine (6MP) * English language proficiency * For AYA \<18, must have informed consent from their caregiver. AYA Exclusion Criteria: * Cognitive impairments that would limit ability to complete measures, determined by the medical team * Absence of inclusion criteria above. Caregiver Inclusion Criteria: * Nominated by the AYA as a primary caregiver involved in cancer care (can be a parent, relative, partner, friend) * English language proficiency Caregiver Exclusion Criteria: \- Absence of inclusion criteria above.

Study sites (1)

IL